| 货号 | AF209-SP |
| 别名 | Cytokine P40; HP40; IL-9homolog of mouse T cell and mast cell growth factor 40; interleukin 9; interleukin-9; p40 cytokine; p40 T-cell and mast cell growth factor; P40; T-cell growth factor P40 | 全称 | Interleukin 9 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human IL-9 in direct ELISAs and Western blots. In direct ELISAs, less than 15% cross-reactivity with recombinant mouse IL-9 and recombinant rat IL-9 is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Neutralization: Measured by its ability to neutralize IL‑9-induced proliferation in the MO7e human megakaryocytic leukemic cell line. Avanzi, G. et al. (1988) Br. J. Haematol. 69:359. The Neutralization Dose (ND50) is typically 2-5 µg/mL in the presence of 5 ng/mL Recombinant Human IL‑9. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3578 (Human); 16198 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IL-9 Gln19-Ile144 Accession # P15248 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Human IL-9 was originally identified as a cytokine found in the conditioned medium of a human T cell leukemia virus type I (HTLV-I) transformed T cell line that is mitogenic for the factor-dependent human megakaryoblastic leukemic cell line, M07e. The cDNA encoding this cytokine was subsequently isolated by functional expression cloning and found to be similar to the mouse T cell growth factor III/P40. This human cytokine and its murine homologue are now designated as human and mouse IL-9. Besides HTLV-I or -II transformed T cell lines, rhIL-9 is also produced by activated human PBLs. Human IL-9 was also reported to be expressed by primary and cultured Hodgkin and Reed-Sternberg (H-RS) cells derived from Hodgkin’s disease patients, suggesting a possible role for rhIL-9 in the development of the pathophysiology of Hodgkin’s disease. Human and murine IL-9 are also capable of enhancing in vitro survival of human T cell lines as well as synergizing with Epo to support erythroid colony formation in vitro. However, the mast cell enhancing activity associated with rmIL-9 has not yet been demonstrated in the human system and no human IL-9-dependent T cell clones have been identified. The gene for rhIL-9 has been mapped to human chromosome 5. As in the mouse system, the human IL-9 cDNA encodes a 144 amino acid residue precursor protein with an 18 amino acid signal peptide that is cleaved to form the mature cysteine-rich protein with a predicted molecular mass of 14 kDa. Human IL-9 contains four potential N-linked glycosylation sites and the native rhIL-9 is a highly glycosylated protein. Human and mouse IL-9 share 56% and 67% homology at the amino acid and nucleotide levels, respectively. Although murine IL-9 is active on human cells, human IL-9 is not active on mouse cells. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
Cell Proliferation Induced by IL‑9 and Neutralization by Human IL‑9 Antibody. Recombinant Human IL‑9 (Catalog # 209-IL) stimulates proliferation in the MO7e human megakaryocytic leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL‑9 (5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑9 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF209). The ND50 is typically 2-5 µg/mL. |
